Enanta Pharmaceuticals | ENTA - Equity Capital And Reserves


Enanta Pharmaceuticals reported $126.59M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 8.66B 961M Dec/2025
Anika Therapeutics USD 143.46M 3.34M Dec/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Heron Therapeutics USD 13.28M 1.6M Dec/2025
Immunic USD 10.5M 23.41M Sep/2025
Incyte USD 5.17B 516.28M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 81.54B 3.07B Dec/2025
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 1.02B 67.04M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Novavax USD -127.75M 28.92M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025